Waltham Matthew, Burnand Kevin, Fenske Christiane, Modarai Bijan, Humphries Julia, Smith Alberto
Cardiovascular Division, Academic Department of Surgery, GKT, King's College, St Thomas' Campus, London, United Kingdom.
J Vasc Surg. 2005 Dec;42(6):1183-9. doi: 10.1016/j.jvs.2005.07.017.
Enhancing thrombus resolution may reduce the long-term complications of venous thrombosis. The aim of this study was to examine whether a sustained release of vascular endothelial growth factor (VEGF) would further improve thrombus recanalization.
Inferior caval vein thrombosis was induced in a cohort of 21 male Wistar rats. A plasmid encoding the human VEGF gene (phVEGF) was injected directly into thrombus (30 to 50 microg) and the muscle adjacent to the inferior vena cava (300 to 400 microg). A plasmid containing the gene encoding beta-galactosidase (pCMVbeta) was injected into the same sites of a separate cohort of rats to act as a control. Tissues were harvested after 1 and 2 weeks, and beta-galactosidase activity was measured to estimate transfection efficiency. Muscle and serum VEGF were measured by enzyme-inked immunosorbent assay. Thrombus size, recanalization, and organization were determined by computer-assisted image analysis.
The efficiency of control plasmid transfection into muscle was about 1%. No serum hVEGF was detected in phVEGF- or pCMVbeta-treated animals. Significantly raised levels of hVEGF (P < .01) were detected in the muscle injected with phVEGF after 2 weeks compared with control muscle. There was a significant reduction in thrombus size of 23% (P < .05) and 48% (P < .001) in phVEGF-treated animals compared with pCMVbeta-treated controls after 1 and 2 weeks, respectively. Thrombus recanalization was a significantly greater in the phVEGF-treated group after 2 weeks (mean 19% +/- 2% [SEM]) compared with controls (mean 13% +/- 2%, P < .01). There were no differences in the thrombus organization score.
VEGF gene therapy of venous thrombus resulted in smaller thrombi with greater recanalization. Angiogenic gene therapy may form the basis of a novel treatment that may improve the resolution of venous thrombi.
Deep vein thrombosis may lead to residual venous obstruction or reflux and result in post-thrombotic complications that are debilitating and have a substantial socioeconomic impact. Enhancing the resolution of venous thrombi may reduce post thrombotic complications.
提高血栓溶解率可能会降低静脉血栓形成的长期并发症。本研究的目的是检验血管内皮生长因子(VEGF)的持续释放是否会进一步改善血栓再通。
在一组21只雄性Wistar大鼠中诱导下腔静脉血栓形成。将编码人VEGF基因的质粒(phVEGF)直接注射到血栓中(30至50微克)以及下腔静脉旁的肌肉中(300至400微克)。将含有编码β-半乳糖苷酶基因的质粒(pCMVbeta)注射到另一组大鼠的相同部位作为对照。1周和2周后采集组织,测量β-半乳糖苷酶活性以评估转染效率。通过酶联免疫吸附测定法测量肌肉和血清中的VEGF。通过计算机辅助图像分析确定血栓大小、再通和机化情况。
对照质粒转染到肌肉中的效率约为1%。在接受phVEGF或pCMVbeta治疗的动物中未检测到血清hVEGF。与对照肌肉相比,2周后在注射phVEGF的肌肉中检测到hVEGF水平显著升高(P <.01)。与pCMVbeta治疗的对照组相比,phVEGF治疗的动物在1周和2周后血栓大小分别显著降低23%(P <.05)和48%(P <.001)。2周后,phVEGF治疗组的血栓再通情况明显优于对照组(平均19% +/- 2% [SEM]),而对照组为(平均13% +/- 2%,P <.01)。血栓机化评分无差异。
静脉血栓的VEGF基因治疗导致血栓更小且再通情况更好。血管生成基因治疗可能构成一种新型治疗方法的基础,该方法可能改善静脉血栓的溶解。
深静脉血栓形成可能导致残余静脉阻塞或反流,并导致血栓形成后并发症,这些并发症使人衰弱并具有重大的社会经济影响。提高静脉血栓的溶解率可能会减少血栓形成后并发症。